Astex
  • Discover Astex
    • Our Mission & Values
    • Our Leadership Team
      • UK – Discovery Research
        • Jeremy Carmichael
        • Harren Jhoti
        • Michelle Jones
        • Neil Jones
        • John Lyons
        • Chris Murray
        • David Rees
        • Nicola Wallis
        • Nicola Wilsher
      • USA – Product Development
        • Mohammad Azab
        • Martin Buckland
        • Harold N. Keer
        • Nipun Davar
        • Yong Hao
        • Joseph Iovino
        • Samuel Jason
        • Nancy Worrell
        • Patti Oto
    • Our History
    • Corporate Social Responsibility
  • R&D
    • Clinical Pipeline
      • Proprietary Products and Programs
        • Guadecitabine (SGI-110) DNMT inhibitor (Hematological Malignancies and Solid Tumors)
        • ASTX029 Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
        • ASTX727 Oral DNMT inhibitor (Hematological Malignancies)
        • ASTX660 Dual IAP Antagonist (Solid Tumors & Lymphomas)
      • Partnered Products and Programs
        • Kisqali® (ribociclib) CDK4/6 inhibitor (Oncology)
        • Balversa® (erdafitinib) FGFr inhibitor (Oncology)
        • AZD5363 PKB/Akt Inhibitor (Oncology)
        • Multiple Targets and Therapeutic Areas
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation
  • Partnering
  • Our People
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Astex in the News
  • Contact
  • Search
  • Menu Menu
You are here: Home1 / 20092 / Astex Granted Orphan Drug Status for AT9283 in AML in USA and Europe

Astex Granted Orphan Drug Status for AT9283 in AML in USA and Europe

23 November 2009/in 2009, News /by webadmin

Astex Granted Orphan Drug Status for AT9283 in AML in USA and Europe

/wp-content/uploads/2019/11/logo_white.png 0 0 webadmin /wp-content/uploads/2019/11/logo_white.png webadmin2009-11-23 12:33:002016-11-28 12:33:21Astex Granted Orphan Drug Status for AT9283 in AML in USA and Europe

Copyright © Astex Pharmaceuticals
All rights reserved

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal

Member of the Otsuka Group

SuperGen Appoints David Bearss, Ph.D., Chief Scientific Officer 2009 AACR: ID of Predicted Biologically Effective Dose of AT7519 in Phase 1...
Scroll to top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok